Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Gynecol Oncol. 2013 Oct 29;132(1):166–175. doi: 10.1016/j.ygyno.2013.10.027

Fig. 3.

Fig. 3

Antitumor effects of PDGFRα blockade in ovarian carcinoma. A) In vivo therapy experiments for 4 different ovarian carcinoma cell lines. Treatment was given for 5–6 weeks (weekly docetaxel i.p. and IMC-3G3 three times a week i.p.). A short-term (2-week) experiment was conducted in the ES2 cell line. †Significant antitumor effect with IMC-3G3 monotherapy was seen in HeyA8, HeyA8-MDR, and ES2. No antitumor effect was seen with IMC-3G3 monotherapy in SKOV3-ip1 tumor-bearing mice. *Significant sensitization of docetaxel antitumor effect was seen in all 4 tested cell lines with co-administration of IMC-3G3 and docetaxel. The bar represents mean with SE. B) Salvage therapy experiment with drug-resistant ovarian carcinoma cell line (HeyA8-MDR-Luc). Treatment was initiated 17 days after cell injection. Borderline significance was seen in the IMC-3G3 monotherapy group as well as in the docetaxel with IMC-3G3 treatment group when compared with the control group (P = 0.07 and .054, respectively). Error bars represent SE. C) 3D tumor vascular imaging is shown in HeyA8-MDR tumor. Docetaxel and IMC-3G3 combination therapy was given for treatment tumor.